Kammrath Betancor Paola, Böhringer Daniel, Maier Philip, Lapp Thabo, Reinhard Thomas
Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ophtha-Lab, Department of Ophthalmology, St. Franziskus Hospital Muenster, Muenster, Germany.
Interact J Med Res. 2024 Sep 10;13:e50106. doi: 10.2196/50106.
Anterior chamber-associated immune deviation (ACAID) is an active immunotolerance mechanism, which is induced by placing antigen into the anterior eye chamber as long as a major surgical trauma is avoided. For this reason, ACAID may be a major contributor to the favorable immunologic outcomes in Descemet membrane endothelial keratoplasty (DMEK). Rodent models have demonstrated the importance of a functional spleen for the development of an ACAID.
This study aimed to investigate whether splenectomy leads to increased rejection rates after DMEK in humans.
A retrospective evaluation was conducted on the course following DMEK at the Eye Center, Medical Center, University of Freiburg, for patients with a self-reported history of splenectomy compared to patients without this condition. Potential study patients were contacted by mail. A questionnaire to self-report splenectomy and the time thereof was sent out. The medical records of all consenting patients at the Eye Center were reviewed for graft survival and immune reactions.
We asked 1818 patients after DMEK to report their history of splenectomy. A total of 1340 patients responded and were included in the study. Of these 1340 patients, 16 (1.2%) reported a history of splenectomy (ie, 26 DMEKs, with 10 patients being transplanted in both eyes and 6 patients being transplanted in 1 eye; median age at surgery 73.7, range 66.7-76.1 y). The remaining patients (1324 patients, ie, 1941 eyes) served as controls, with 1941 DMEKs (median age at surgery 71.5, range 64.1-77.2 y). Five (19%) out of the 26 eyes from the splenectomy group required a second transplant due to dislocation (n=2.8%), failure (n=2.8%), and rejection (n=1.4%). Kaplan-Meier analysis revealed no relevant difference compared with controls.
Our results suggest that splenectomy has no major effect on the outcome following DMEK. Subsequent, ACAID may not be the main reason for the favorable immunological outcomes in DMEK, or the camero-splenic axis may be subordinate in humans. However, we only included 16 patients who underwent splenectomy, so it might be possible that we missed a minor effect.
前房相关免疫偏离(ACAID)是一种主动免疫耐受机制,只要避免重大手术创伤,将抗原注入眼前房即可诱导产生。因此,ACAID可能是Descemet膜内皮角膜移植术(DMEK)良好免疫结果的主要促成因素。啮齿动物模型已证明功能性脾脏对ACAID形成的重要性。
本研究旨在调查脾切除术后人类DMEK排斥率是否会增加。
对弗赖堡大学医学中心眼科中心接受DMEK手术的患者进行回顾性评估,将有脾切除自我报告史的患者与无此情况的患者进行比较。通过邮件联系潜在的研究患者。发送一份自我报告脾切除及其时间的问卷。查阅眼科中心所有同意参与研究的患者的病历,以了解移植物存活情况和免疫反应。
我们询问了1818例接受DMEK手术的患者其脾切除史。共有1340例患者回复并纳入研究。在这1340例患者中,16例(1.2%)报告有脾切除史(即26次DMEK手术,其中10例患者双眼移植,6例患者单眼移植;手术时中位年龄73.7岁,范围66.7 - 76.1岁)。其余患者(1324例患者,即1941只眼)作为对照,有1941次DMEK手术(手术时中位年龄71.5岁,范围64.1 - 77.2岁)。脾切除组的26只眼中有5只(19%)因脱位(n = 2.8%)、失败(n = 2.8%)和排斥(n = 1.4%)需要进行二次移植。Kaplan - Meier分析显示与对照组无显著差异。
我们的结果表明,脾切除对DMEK术后结果无重大影响。因此,ACAID可能不是DMEK良好免疫结果的主要原因,或者在人类中眼 - 脾轴可能并不重要。然而,我们仅纳入了16例接受脾切除的患者,所以有可能我们遗漏了轻微影响。